Barbara Musial
Senior Scientist, Oncology Safety AstraZeneca
Barbara is a Senior Scientist in Oncology Safety, spending previous five years in Cardiovascular & Renal Bioscience department of AstraZeneca. Broad experience in human in vitro disease models development from efficacy to safety studies. Barbara’s current focus is understanding the mechanism of action of ADC-driven toxicities in healthy tissues. She was awarded her PhD in 2015 from the University of Cambridge, at the Institute of Metabolic Science. She investigated a molecular signalling of insulin in healthy and diseased (diabetic & obese) pregnancy.
Seminars
Monday 23rd February 2026
Advancing Safety Assessment of ADCs: Assessing Opportunities & Challenges in In Vitro Model Applications
10:00 am
- Overviewing ADC toxicities and general strategy at the discovery toxicology stage
- Exploring examples of applications of advanced in vitro models to complement ADC safety analysis alongside in vivo tools
- Understanding key gaps and challenges to overcome for in vitro ADC safety assessments
